Growth Hormone Potentiates 17β-Estradiol-Dependent Breast Cancer Cell Proliferation Independently of IGF-I Receptor Signaling

Dana L. Felice, Lamiaa El-Shennawy, Shuangping Zhao, Daniel L. Lantvit, Qi Shen, Terry G. Unterman, Steven M. Swanson, and Jonna Frasor

Departments of Physiology and Biophysics (D.L.F., S.Z., J.F.), Biopharmaceutical Science (L.E.-S.), Medicine (T.G.U.), and Medicinal Chemistry and Pharmacognosy (D.L.L., Q.S., S.M.S.), University of Illinois at Chicago, Chicago, Illinois 60612

Estrogen action in mammary gland development and breast cancer progression is tightly linked to the GH/IGF-I axis. Although many of the effects of GH on mammary gland growth and development require IGF-I, the extent to which GH action in breast cancer depends on IGF-I is not known. We examined GH action in a panel of estrogen receptor-positive breast cancer cell lines and found that T47D cells express significant levels of GH receptor and that GH significantly enhances 17β-estradiol (E2)-stimulated proliferation in these cells. GH action in the T47D cells was independent of changes in IGF-I and IGF-I receptor (IGF-IR) expression and IGF-IR signaling, suggesting that GH can exert direct effects on breast cancer cells. Although E2-dependent proliferation required IGF-IR signaling, the combination of GH and E2 overcame inhibition of IGF-IR activity to restore proliferation. In contrast, GH required both Janus kinase 2 and epidermal growth factor receptor signaling for subsequent ERK activation and potentiation of E2-dependent proliferation. Downstream of these pathways, we identified a number of immediate early-response genes associated with proliferation that are rapidly and robustly up-regulated by GH. These findings demonstrate that GH can have important effects in breast cancer cells that are distinct from IGF-IR activity, suggesting that novel drugs or improved combination therapies targeting estrogen receptor and the GH/IGF axis may be beneficial for breast cancer patients. (Endocrinology 154: 3219–3227, 2013)

Estrogens, such as 17β-estradiol (E2), are a major factor in the initiation and progression of breast cancer. Endocrine therapies targeting E2 production or estrogen receptor (ER) activity have proven effective in most patients with ER+ breast cancers. However, resistance to these therapies can occur in up to 50% of these patients. Therefore, additional therapeutic strategies are needed for women with ER+ breast tumors.

Targeting the IGF-I pathway has been of particular interest, given the tight association between ER and the IGF-I receptor (IGF-IR) signaling pathway. Cross talk between these factors can occur on many levels including ER and IGF-IR interaction (1, 2), E2 activation of the IGF-I pathway (3), and up-regulation of IGF-I signaling components by E2 (4–7). IGF-I is also implicated in breast cancer resistance to endocrine therapies (8–10) and can activate a gene signature that associates with luminal B breast tumors, a subtype of ER+ tumors with poor outcome (11). Based on this evidence, cotargeting both ER and IGF-IR seems to be a reasonable therapeutic approach for patients with ER+ breast cancer that fail to respond to endocrine therapy. In fact, inhibition of IGF-IR can block E2-stimulated proliferation in vitro (3), and IGF-IR targeted therapy improves the efficacy of antiestrogens in the breast cancer cell lines BT474 and MCF-7 (12). However, despite the success of IGF-IR-targeted therapies in vitro and preclinical in vivo models, outcomes of clinical trials have been disappointing (13–15). For example, a random-
ized phase II trial found no difference in progression-free survival when an anti-IGF-IR antibody (AMG 479) was given in addition to endocrine therapy (exemestane or fulvestrant) among postmenopausal women with ER+ metastatic breast cancer (16). Furthermore, a recent study has shown that tamoxifen-resistant tumors, representing the patients most likely to be entered into a clinical trial testing an IGF-targeted therapy, actually lose IGF-IR expression and thus do not respond to such treatments (17).

Another possible reason for failure of IGF-IR therapies could be that they increase circulating GH levels (18, 19) through the disruption of a negative feedback loop between the liver and the pituitary gland (20). Several lines of emerging evidence implicate a role for GH in breast cancer. A recently published 22-year long study found cancer to be virtually nonexistent among a GH receptor (GHR)-deficient population in Ecuador (21). GH signaling was the pathway third most highly associated with breast cancer risk in a genome-wide association study (22). Furthermore, GHR expression is higher in breast tumors vs adjacent normal tissue (23), and expression of autocrine GH in mammary carcinomas was found to predict worse survival outcomes (24). Despite this evidence, the role of GH in human breast cancer has not been well studied.

Although many of GH’s actions on growth and development of the rodent mammary gland are mediated by IGF-I (as reviewed in References 25 and 26), here we examined the direct role of GH in ER+ breast cancer cell lines. We found that GH is capable of potentiating the effects of E2 on proliferation in cells expressing high levels of GHR. Importantly, GH was capable of overcoming the growth-suppressive effects of IGF-IR tyrosine kinase inhibition, suggesting that GH action may, in fact, be a plausible cause of IGF-IR inhibitor failure in the clinic. In addition, we have dissected the pathways activated directly by GH in breast cancer cells and found that Janus kinase 2 (JAK2), epidermal growth factor receptor (EGFR), and ERK may all play essential roles in mediating the effects of GH on both the proliferation and expression of immediate early target genes.

Materials and Methods

Reagents

Recombinant human GH was purchased from Dr A. F. Parlow (National Hormone and Peptide Program, National Institute of Diabetes and Digestive and Kidney Diseases) and reconstituted in PBS with 0.1% BSA. E2 was purchased from Sigma (St Louis, Missouri). IGF-I was purchased from R&D Systems (Minneapolis, Minnesota). ICI 182,780 (ICI) was purchased from Tocris (Bristol, United Kingdom). NVP-AEW541 (AEW541) was generously provided by Novartis Pharmaceuticals (Basel, Switzerland). AG1478 was purchased from Cayman Chemicals (Ann Arbor, Michigan); gefitinib from LC Laboratories (Woburn, Massachusetts); U0126 from Calbiochem (EMD Millipore, Billerica, Massachusetts); and AZD1480 from Selleckchem (Houston, Texas). Antibodies used for Western blotting of cell extracts were as follows: phospho-ERK (Santa Cruz Biotechnology, Santa Cruz, California; sc-7383); ERK (Santa Cruz Biotechnology; sc-94); phospho-IGF-IR (Cell Signaling Technology, Danvers, Massachusetts; number 3024); IGF-IR (Cell Signaling; number 3027); phospho-signal transducer and activator of transcription (STAT)-5 (Y694) (Cell Signaling; number 9359 and number 9351); STAT5 (Cell Signaling; number 9363); ERα (NeoMarkers, Fremont, California; Ab-21 H222); EGFR (Cell Signaling; number 2646); and β-actin (Sigma; clone AC-15, number A5441). Small interfering RNA targeting JAK2 and a nontargeting negative control were purchased from Ambion (Life Technologies, Grand Island, New York).

Cell culture

All cell lines were routinely maintained in RPMI 1640 (Invitrogen Life Technologies, Grand Island, New York) with phenol red containing 10% fetal bovine serum, as described previously (27). Growth media for MCF-7 and BT474 cells contained 6 ng/mL insulin. Cells seeded for experiments were cultured in RPMI 1640 without phenol red, containing 5% charcoal-dextran-stripped fetal bovine serum for 2–3 days prior to hormone treatment.

Proliferation assays

The methylene blue assay was carried out as described previously (28). Briefly, media were removed and cells were rinsed with PBS. Cells were then incubated for 1 hour at 37°C in methylene blue fixing and staining solution (Hanks’ balanced salt solution with 1.25% glutaraldehyde and 0.6% methylene blue). After removing the solution and rinsing in distilled water, the stain was eluted for 15 minutes with gentle agitation using elution solution (49% PBS, 50% ethanol, 1% acetic acid). Absorbance was read on an automated plate reader (Synergy HT; BioTek, Winooski, Vermont) at a 562-nm wavelength. Data represent relative cell numbers, presented as a percentage of control. The DNA assay was carried out as previously described (29). After hormone treatment, media were removed and cells were covered with fresh RPMI 1640 without serum or additives, and Hoechst dye (Invitrogen) was added for a final concentration of 1.25 μg/mL. Cells were incubated for 1 hour at 37°C, and fluorescence (excitation 360/40, emission 460/40) was measured. DNA content was calculated from a standard curve and is reported as a percentage of vehicle control. The 5-bromo-2′-deoxyuridine (Brdu) assay was carried out according to the manufacturer’s instructions (BrDU cell proliferation assay kit; Millipore). Absorbance, reflecting incorporation of Brdu into the DNA of the cells and thus transition through the cell cycle, was read at 490 nm wavelength.

Western blot

Whole-cell extracts were prepared using M-PER (Thermo Scientific, Rockford, Illinois) and protein concentrations were measured using the bicinchoninic acid method (Thermo Scien-
tific). Proteins were separated by SDS-PAGE (10% Tris-HCl precast gels; Bio-Rad Laboratories, Hercules, California), transferred to nitrocellulose membranes (Thermo Scientific), blocked for 1 hour in buffer containing 5% nonfat dry milk (Lab Scientific, Livingston, New Jersey) or 5% BSA, and incubated with the appropriate primary antibody overnight. The next day, secondary antibody was applied and the signal was visualized on a Molecular Imager Chemidoc XR5 (Bio-Rad Laboratories), using the Pierce Supersignal West Pico chemiluminescent substrate (Thermo Scientific). In the case of phosphoproteins, membranes were first probed for the phosphoprotein, stripped with Re-Blot Plus Mild antibody stripping solution (Millipore) and then re-probed for the respective total protein.

RT-quantitative PCR (QPCR)
RNA was isolated and QPCR performed using the ∆Δcycle threshold method with 36B4 as the internal control, as described previously (30). Primer sequences are listed in Supplemental Table 1, published on The Endocrine Society’s Journals Online website at http://endo.endojournals.org.

Statistics
Data are presented as mean ± SEM from at least 3 independent determinations. Statistical analyses consisted of 1- or 2-way ANOVA followed by Bonferroni posttest, or t test, as appropriate.

Results
GH and E2 enhance proliferation in T47D breast cancer cells
To examine whether GH has direct effects on human breast cancer cells, we first examined GHR mRNA expression in several ER+ breast cancer cell lines. T47D cells showed the highest level of expression (Figure 1A) compared with ZR75-1, BT474, and MCF-7 cells. It should be noted that the pattern of expression of prolactin receptor (PRLR) mRNA was similar to GHR mRNA among the 4 cell lines in that both were most highly expressed in T47D cells. MCF-7 cells, on the other hand, expressed higher levels of both ERα and IGF-IR mRNA (Supplemental Figure 1). E2 stimulated proliferation in all ER+ cell lines (Figure 1B and Supplemental Figure 2). In contrast, GH action was evident only in T47D cells (Figure 1B), which may be explained by the higher relative GHR expression. In T47D cells, GH caused a slight increase in the cell number that did not consistently reach significance. Notably, however, E2+GH significantly increased cell number compared with E2 alone in T47D cells (Figure 1B). To verify that the increase in cell number was due to enhanced proliferation rather than reduced cell death, a BrdU incorporation assay was performed and confirmed that GH primarily acts to potentiate E2-dependent proliferation (Figure 1C). In addition, the ER antagonist ICI significantly reduced proliferation in response to E2 as well as E2+GH (Figure 1D). ICI did not affect the basal rate of cell proliferation because the cells are grown under nonestro-genic conditions (phenol-red free media supplemented with charcoal-dextran stripped serum). GH had no effect on ERα mRNA or protein expression in T47D cells (Supplemental Figure 3). These results suggest that GH is able to promote E2-dependent proliferation in ER+ breast cancer cells that express higher levels of GHR.

GH potentiates E2-dependent proliferation in a JAK2/ERK/EGFR-dependent manner but independently of IGF-IR activation
To examine whether the IGF-I pathway was involved in GH’s ability to potentiate E2-dependent proliferation, IGF-I expression was measured in T47D cells. IGF-I mRNA levels were unaffected by GH, E2, or GH+E2 (Figure 2A), and secreted IGF-I protein was below detectable limits of the ELISA in all treatment groups (Figure 2B), indicating that the effect of GH on cell proliferation is not due to increased expression of IGF-I. Next, we investigated the influence of hormone treatment on IGF-IR expression and activity. Although E2 up-regulates IGF-IR expression, as expected, GH had no effect, either alone or in combination with E2 (Figure 2C). Furthermore, GH+E2 treatment does not affect phosphorylation of
did not disrupt the ability of GH suggested in previous studies (31). In contrast, AEW541 E2-dependent breast cancer cell proliferation is independent of IGF-I production and IGF-IR signaling and that GH can blunt the effectiveness of IGF-IR inhibitors on cancer cell growth.

GH activation of 2 major signaling pathways, JAK2/STAT5 and ERK, was detected in T47D cells treated with GH or GH+E2 but not by E2 alone (Figure 3A). Because the doses of GH and E2 used cause maximal proliferation (data not shown), and because E2 did not activate STAT5 or ERK in these cells, our findings suggest that GH activation of these pathways does not depend on E2 action. Neither pathway was significantly activated in other ER+ cell lines (data not shown), suggesting that the ability of GH to regulate these pathways correlates with its ability to potentiate proliferation. Previous studies have suggested that GH may use JAK2 and EGFR to activate ERK in various cell types, including preadipocyte and liver cells (32–35), but this has not been well studied in breast cancer cells. To examine how ERK is activated in T47D cells, specific inhibitors of JAK2 (AZD1480) and EGFR (AG1478) were used. We found that pharmacological blockade of either EGFR or JAK2 reduced the phosphorylation of both STAT5 and ERK by GH (Figure 3B), whereas the blockade of IGF-IR did not (Supplemental Figure 4). However, treatment with E2, GH, or both had no effect on EGFR expression (Supplemental Figure 5). These observations suggest that GH uses both JAK2 and EGFR to activate two of its downstream effectors, STAT5 and ERK.

We next examined whether these pathways are required for GH-mediated cell proliferation. The JAK2 inhibitor, AZD1480, had no effect on E2 action but inhibited the ability of GH to potentiate E2-stimulated proliferation (Figure 4A), indicating that JAK2 is not required by E2 but is essential for GH to enhance E2-stimulated proliferation. Inhibition of ERK activation by U0126 (Figure 4B and Supplemental Figure 6A) or AS703026 (Supplemental Figure 6, B and C), a novel MAPK kinase (MEK) inhibitor, disrupted the ability of E2 and GH+E2 to stimulate cell proliferation. Similarly, inhibition of EGFR with AG1478 (Figure 4C) or gefitinib (data not shown) prevented the effects of E2 and GH+E2 on cell proliferation. AG1478 also abrogated STAT5 phosphorylation (Figure 3B). However, because STAT5 activation is required only for GH enhancement of E2-stimulated proliferation and not for E2 action itself (Figure 4A) and because specific MEK inhibitors dramatically impact proliferation (Figure 4B and Supplemental Figure 6), we conclude that the effects of AG1478 on proliferation most likely are due to inhibition of EGFR-mediated ERK activation. Together these findings indicate that the JAK2 pathway is essential for GH's ability to potentiate E2-dependent proliferation and that ERK and EGFR ac-

**Figure 2.** GH potentiates E2-stimulated T47D cell proliferation independently of IGF-I expression or IGF-IR activation. A, T47D cells were treated with 500 ng/mL GH for 24 hours. IGF-I mRNA expression was determined by QPCR. B, T47D cells were treated as in A, and conditioned media were collected. Levels of IGF-I protein were measured by ELISA. C, T47D cells were treated with hormones for 24 hours, after which total levels of IGF-IR protein were determined by Western blot. D, T47D cells were pretreated for 2 hours with 2 μM AEW541, an inhibitor of IGF-IR tyrosine kinase activity, followed by 30 minutes of treatment with GH+E2 or 50 ng/mL IGF-I. Phospho- and total IGF-IR levels were examined by Western blot to demonstrate the effectiveness of the inhibitor. E, T47D cells were treated with E2, E2+GH, or E2+IGF-I in the presence of 1 μM AEW541 or vehicle (dimethylsulfoxide (DMSO)) for 5 days. Proliferation was measured by the methylene blue assay. Similar results were found using the DNA assay (data not shown). Bars with different letters are significantly different (P < .05).
Regulators associated with cell proliferation and thereby potentiate E2-dependent proliferation.

**Discussion**

In this study, we have demonstrated that GH plays a significant role in human breast cancer cell proliferation by acting directly on human breast cancer cells to increase E2-dependent cell proliferation. Not only are these effects likely IGF-I independent because GH does not up-regulate IGF-I in the cells, nor does GH affect IGF-IR expression or activation, but GH can also overcome the growth-inhibitory effect of an IGF-IR inhibitor, indicating a potential mechanism by which therapeutics targeting IGF-IR may fail in women with ER+ breast cancer.

Although many of GH’s actions on growth and development, including in the rodent mammary gland, are mediated by IGF-I (as reviewed in References 25 and 26), GH acting independently of IGF-1 is not unprecedented. For example, a GHR/IGF-I double knockout stunted somatic growth more severely than either single knockout alone, a compelling indication that GH and IGF-I have both independent and overlapping functions (40). GH also has many important roles in metabolism that are largely thought to be IGF-I independent, although some uncertainty still surrounds this issue, as reviewed by Vijayakumar et al (41). Briefly, GH increases lipolysis in adipose tissue. In the liver, in which IGF-IR expression is low, GH stimulates bile acid production, hepatic glucose production, and triglyceride uptake and storage by reducing lipolysis and lipid oxidation and increases lipogenesis. GH also inhibits insulin action in both adipose tissue and the liver (41). On the other hand, GH has been shown to require IGF-IR to stimulate STAT5 activation and proliferation in osteoblasts, independently of its ability to stimulate IGF-I expression (42). Activation of ERK, however, did not require IGF-IR. In preadipocytes and pancreatic islet β-cells, GH induces complex formation of GHR, JAK2, and IGF-IR, whereas in murine osteoblasts and β-cells, GH stimulation of STAT5 depends on the presence of the IGF-IR. However, in all 3 cell types, these actions of GH occurred independently of the tyrosine kinase activity of the IGF-IR (43–45). Whether the presence of...
IGF-IR is also required for the effects of GH in T47D breast cancer cells requires further investigation. To our knowledge, this is the first report that GH can act independently of IGF-1 production and IGF-IR tyrosine kinase activity on E2-stimulated proliferation in human breast cancer cells.

The question of how GH bypasses the requirement for IGF-IR signaling to enhance E2-stimulated proliferation remains. The GHR is likely involved because T47D cells express GHR and also respond to GH by activating signaling pathways and potentiating proliferation. However, human GH is known to also bind and activate PRLR (46–48), and a recent report of functional GHR/PRLR dimers responding to GH in T47D breast cancer cells has emerged (49). In fact, in that study antagonism of both GHR and PRLR was required to abrogate GH-stimulated STAT5 activation. Furthermore, a recent finding showed that the reduction of PRLR expression in T47D cells increases the preference of GH to bind to GHR (vs the PRLR) as well as increasing the sensitivity to GH response (50). Thus, we cannot exclude the possibility that both PRLR and GHR, perhaps in the form of heterodimers, may play a role in the GH potentiation of E2 action in breast cancer cells. Interestingly, the synergistic effects of prolactin (PRL) on E2-stimulated expression of ER target genes in T47D cells have been described (51), indicating GH and PRL may have similar roles. We have observed that GH may also can potentiate E2-stimulated expression of some ER target genes in T47D cells (Felice, D. L. and J. Frasor, unreported observation) but whether GH and PRL have similar gene regulatory effects is not known.

In the present study, we find that GH activates JAK2/STAT5 and that this is required for enhanced E2-dependent proliferation. In addition, MEK/ERK signaling is activated by GH and this occurs downstream of both JAK2 and EGFR. Although links between these pathways have been established, the mechanisms of interaction appear to be complex and cell type specific. For example, GH has been shown to phosphorylate EGFR via GHR/JAK2 signaling, leading to the activation of MAPK signaling in mouse liver and Chinese hamster ovary cells (33, 34). However, in preadipocytes GH can phosphorylate EGFR via ERK, thereby delaying EGFR degradation and thus prolonging signaling (32).

In addition, the GH activation of STATs and ERK has been shown to be dependent on JAK2 in preadipocytes and hepatoma cells (35). GH and EGF can synergize in mouse preadipocytes, converging on ERK activation, whereas PRL and platelet-derived growth factor have a similar synergy in T47D cells (52). From our studies, we can conclude that in T47D breast cancer cells, GH uses both JAK2 and EGFR to activate ERK by a mechanism which does not require IGF-IR tyrosine kinase activity. It is difficult to know what role ERK and EGFR play in mediating the effect of GH on E2 action because the inhibition of either pathway prevented E2-stimulated proliferation, even in the absence of GH. Furthermore, although hormone treatments did not affect EGFR expression (Supplemental Figure 5), EGFR action is also required for ERK and STAT5 activation (Figure 3B).

Nevertheless, GH activation of these pathways is likely to be important because all three (JAK2/ERK/EGFR) were essential for the GH regulation of IEGs previously associated with GH action and/or cellular proliferation. Previous studies have shown that GH activation of ERK leads to the up-regulation of IEGs encoding for transcription factor genes, including *FOS*, *JUN*, *ATF3*, and *EGR1*, in preadipocytes (53), and EGF induces expression of many of the same genes in MCF-10A cells (39).

Our findings suggest that the GH regulation of these genes in T47D breast cancer cells is ERK dependent and that the effects of JAK2/EGFR inhibition are through loss of ERK activation. However, other pathways and transcription factors may also be involved. For example, *ATF3* was identified as a novel gene target of GH that is regulated in a CCAAT/enhancer-binding protein-β-dependent manner (53), and *FOS* also is induced by GH in preadipocytes in a JAK2-, MEK/ERK-, and CCAAT/enhancer-binding protein-β-dependent manner (38, 54–57).

It is important to note that most of the GH-regulated IEGs that we examined have the potential to play important roles in breast cancer. *FOS/JUN*, for example, constitute the activating protein-1 transcription factor, which regulates a number of genes involved in multiple cancer-related processes, including proliferation, differentiation, hypoxia, angiogenesis, metastasis, apoptosis, and invasion (as reviewed in Reference 58). Activating transcrip-
tion factor 3 (ATF3) protein expression was found to be higher than matched normal mammary gland tissue in 48% of breast tumors examined (59), and transgenic mice overexpressing human ATF3 in the basal epithelium of the mammary gland develop mammary cancer after parity, which implicates ATF3 as an oncogene (60). Early growth response protein 1 is a zinc finger transcription factor (61, 62) that can play a role in cell proliferation, migration, and invasion (63). On the other hand, the role that GH-induced ZFP36 plays in T47D cells remains unclear. ZFP36, which was first identified as a growth-factor induced gene in mouse 3T3 cells (64), acts as a regulator of mRNA degradation (65). Considering the important roles of these IEGs, we speculate that they are essential players in GH’s ability to potentiate E2-stimulated proliferation. However, it is interesting to note that GH alone, which leads to significant pathway activation and gene expression, does not have much impact on T47D cell proliferation in the absence of E2.

In conclusion, we have demonstrated that GH has direct actions on human breast cancer cells that are independent of changes in IGF-I production, IGF-IR expression, and IGF-IR activation and can overcome IGF-IR blockade, using JAK2/STAT signaling and potentially EGFR and ERK to do so. These findings are clinically relevant for women who may be directed to IGF-IR inhibitor therapies, which may elevate circulating levels of GH. The possibility of GH-regulated early genes playing a role in potentiation of E2 action is intriguing and warrants further attention. Importantly, further research will be necessary to decipher the appropriate biomarker to predict these actions of GH in breast tumors. Finally, this study highlights the importance of regarding GH as having both IGF-I-dependent and -independent functions in breast cancer biology.

Acknowledgments

We thank Dr Irida Kastrati and Bryant Marure for their technical expertise.

Address all correspondence and requests for reprints to: Jonna Frasor, PhD, Department of Physiology and Biophysics, University of Illinois at Chicago, 835 South Wolcott Avenue, MC 901, Chicago, Illinois 60612. E-mail: jfrasor@uic.edu.

This work was supported in part by American Cancer Society Grant 119168-RSG-10-187--01-TBE (to J.F.) and National Institutes of Health Grant T32 HL07692--21 (to D.L.F.).

Disclosure Summary: The authors have nothing to disclose.

References

17. Berelowitz M, Szabo M, Frohman LA, Firestone S, Chu L, Hintz RL. Somatotropin-C mediates growth hormone negative feedback by

Members have FREE online access to current endocrine Clinical Practice Guidelines.

www.endo-society.org/guidelines